序号 |
标题 |
次数 |
作者 |
发布时间 |
65386 |
cas:2504147-59-3 MC (C5)-Val-Cit |
123 |
zyl |
2024-12-19 |
65387 |
Boc-PEG4-Val-Ala-PAB,可降解的ADC连接体 |
132 |
WYQ |
2024-12-19 |
65388 |
cas:2058075-34-4,DGN549-C , ADC试剂 |
64 |
kx |
2024-12-19 |
65389 |
CAS: 1639939-40-4,Mal-Val-Ala-PAB-PNP,马来酰亚胺-VAL-ALA-PAB-PNP |
119 |
WYQ |
2024-12-19 |
65390 |
Fmoc-VC-PAB-Duocarmycin SA, ADC试剂 |
91 |
kx |
2024-12-19 |
65391 |
Mal-PEG4-Val-Ala-PAB,可降解的ADC(抗体偶联药物)连接子 |
139 |
WYQ |
2024-12-19 |
65392 |
Mal-PEG1-Val-Cit-OH的介绍 |
119 |
zyl |
2024-12-19 |
65393 |
MC-vc-PAB-Monomethyl dolastatin10, ADC试剂 |
80 |
kx |
2024-12-19 |
65394 |
CAS: 1870916-87-2,Mal-Val-Ala-PAB,马来酰亚胺-缬氨酸-丙氨酸-对氨基苯甲酸 |
84 |
WYQ |
2024-12-19 |
65395 |
cas:2395887-69-9 Mal-PEG2-Val-Cit-PAB-PNP |
79 |
zyl |
2024-12-19 |
65396 |
SuO-Val-Cit-PAB-MMAE, ADC试剂 |
71 |
kx |
2024-12-19 |
65397 |
Mal-PEG4-Val-Ala-PAB-PNP的介绍 |
82 |
zyl |
2024-12-19 |
65398 |
CAS: 2348405-93-4,DBCO-PEG4-Val-Ala-PAB-PNP |
60 |
WYQ |
2024-12-19 |
65399 |
CAS: 2348405-92-3,DBCO-PEG4-Val-Ala-PAB |
71 |
WYQ |
2024-12-19 |
65400 |
cas:2112738-13-1 Mal-amido-PEG2-Val-Cit-PAB-PNP |
72 |
zyl |
2024-12-19 |
65401 |
Azido-PEG4-Val-Ala-PAB,分子式:C29H48N8O9 |
63 |
WYQ |
2024-12-19 |
65402 |
cas:2055896-86-9,MC-Val-Cit-PAB-tubulysin5a , ADC试剂 |
80 |
kx |
2024-12-19 |
65403 |
Azido-PEG8-Val-Cit-PAB-PNP |
57 |
zyl |
2024-12-19 |
65404 |
cas:2055896-83-6,MC-Val-Cit-PAB-carfilzomib , ADC试剂 |
103 |
kx |
2024-12-19 |
65405 |
MAL-di-EG-Val-Cit-PAB-MMAF, ADC试剂 |
71 |
kx |
2024-12-19 |
65406 |
cas:2353409-45-5 endo BCN-PEG3-VC-PFP Ester |
80 |
zyl |
2024-12-19 |
65407 |
Hydrazone-doxorubicin, ADC试剂 |
144 |
kx |
2024-12-19 |
65408 |
DBCO-C4-Val-Cit-PABC-PNP |
59 |
zyl |
2024-12-19 |
65409 |
cas:644981-35-1 Val-Cit-PAB-MMAE |
70 |
zyl |
2024-12-19 |
65410 |
cas:170908-81-3,DOTA-NHS ester ,1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 1-(2,5-二氧代-1-吡咯烷基)酯 |
63 |
kx |
2024-12-19 |
65411 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE的介绍 |
72 |
zyl |
2024-12-19 |
65412 |
cas:2259318-50-6,MA-PEG4-VA-PBD , ADC试剂 |
86 |
kx |
2024-12-19 |
65413 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
57 |
WYQ |
2024-12-19 |
65414 |
CAS: 2768446-73-5,DBCO-Val-Cit-PAB-MMAE |
69 |
WYQ |
2024-12-19 |
65415 |
MC-vc-PAB-C6-a-amanitin, ADC试剂 |
59 |
kx |
2024-12-19 |
65416 |
cas:663598-98-9,2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate,ADC定制 |
75 |
wyh |
2024-12-19 |
65417 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
79 |
zyl |
2024-12-19 |
65418 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate,ADC定制 |
86 |
wyh |
2024-12-19 |
65419 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
109 |
zyl |
2024-12-19 |
65420 |
Gly3-vc-PAB-MMAE, ADC试剂 |
87 |
kx |
2024-12-19 |
65421 |
CAS: 1869126-64-6, Azido-PEG4-Val-Cit-PAB-MMAE |
68 |
WYQ |
2024-12-19 |
65422 |
cas:2353409-54-6 , Mal-amido-PEG8-Val-Gly,ADC定制 |
81 |
wyh |
2024-12-19 |
65423 |
Azido-PEG4-Val-Ala-PAB-PNP |
84 |
zyl |
2024-12-19 |
65424 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
71 |
h |
2024-12-19 |
65425 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid,ADC定制 |
82 |
wyh |
2024-12-19 |
65426 |
CAS: 1343476-44-7,Val-Ala-PAB-OH |
68 |
WYQ |
2024-12-19 |
65427 |
MC-PBD, ADC试剂 |
79 |
kx |
2024-12-19 |
65428 |
Mal-Val-Ala-PAB的介绍 |
80 |
zyl |
2024-12-19 |
65429 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
66 |
h |
2024-12-19 |
65430 |
Azide-PEG3-Val-Cit-PAB-MMAF,叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
67 |
WYQ |
2024-12-19 |